Bridge Therapeutics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $321K

  • Investors
  • 3

Bridge Therapeutics General Information

Description

Operator of a pharmaceutical company intended for the treatment of chronic pain in opioid-experienced patients. The company offers a better delivery of buprenorphine-naloxone for opioid use disorder (OUD) and drug combination, enabling medical researchers to improve the lives of patients living with chronic pain by developing new approaches to pain management that are safer, more effective, and non-addictive.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 217 Country Club Park
  • Suite 325
  • Birmingham, AL 35213
  • United States
+1 (205)
Primary Industry
Drug Discovery
Corporate Office
  • 217 Country Club Park
  • Suite 325
  • Birmingham, AL 35213
  • United States
+1 (205)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bridge Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 18-Dec-2023 $321K Completed Clinical Trials - Phase 4
3. Early Stage VC 01-Jun-2020 Completed Clinical Trials - General
2. Early Stage VC (Series A) 01-Dec-2019 $3.3M $5.3M Completed Clinical Trials - General
1. Early Stage VC (Series AA) 24-Apr-2019 $2M $2M Completed Clinical Trials - General
To view Bridge Therapeutics’s complete valuation and funding history, request access »

Bridge Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series AB
Series AA
To view Bridge Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Bridge Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a pharmaceutical company intended for the treatment of chronic pain in opioid-experienced patients. The comp
Drug Discovery
Birmingham, AL
7 As of 2026

Hilliard, OH
 

Palo Alto, CA
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Bridge Therapeutics Competitors (12)

One of Bridge Therapeutics’s 12 competitors is Sollis Therapeutics, a Venture Capital-Backed company based in Hilliard, OH.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sollis Therapeutics Venture Capital-Backed Hilliard, OH
Semnur Pharmaceuticals Formerly VC-backed Palo Alto, CA
Centrexion Therapeutics Venture Capital-Backed Boston, MA
Xalud Therapeutics Venture Capital-Backed New York, NY
Brixton Biosciences Venture Capital-Backed Cambridge, MA
You’re viewing 5 of 12 competitors. Get the full list »

Bridge Therapeutics Patents

Bridge Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-10195206-B2 Two-component pharmaceutical composition for the treatment of pain Inactive 14-Jun-2005
US-20060281775-A1 Two-component pharmaceutical composition for the treatment of pain Inactive 14-Jun-2005
US-20100093712-A1 Two-component pharmaceutical composition for the treatment of pain Active 14-Jun-2005
US-20140080818-A1 Two-component pharmaceutical composition for the treatment of pain Active 14-Jun-2005
US-20190388431-A2 Two-component pharmaceutical composition for the treatment of pain Inactive 14-Jun-2005 A61K31/5415
To view Bridge Therapeutics’s complete patent history, request access »

Bridge Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bridge Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angel (individual) Minority
EJME Real Estate Minority
Keiretsu Forum Angel Group Minority
To view Bridge Therapeutics’s complete investors history, request access »

Bridge Therapeutics FAQs

  • When was Bridge Therapeutics founded?

    Bridge Therapeutics was founded in 2016.

  • Where is Bridge Therapeutics headquartered?

    Bridge Therapeutics is headquartered in Birmingham, AL.

  • What is the size of Bridge Therapeutics?

    Bridge Therapeutics has 7 total employees.

  • What industry is Bridge Therapeutics in?

    Bridge Therapeutics’s primary industry is Drug Discovery.

  • Is Bridge Therapeutics a private or public company?

    Bridge Therapeutics is a Private company.

  • What is Bridge Therapeutics’s current revenue?

    The current revenue for Bridge Therapeutics is .

  • How much funding has Bridge Therapeutics raised over time?

    Bridge Therapeutics has raised $11.6M.

  • Who are Bridge Therapeutics’s investors?

    , EJME, and Keiretsu Forum have invested in Bridge Therapeutics.

  • Who are Bridge Therapeutics’s competitors?

    Sollis Therapeutics, Semnur Pharmaceuticals, Centrexion Therapeutics, Xalud Therapeutics, and Brixton Biosciences are some of the 12 competitors of Bridge Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process